Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
Subscribe To Our Newsletter & Stay Updated
